Company / Shareholders' Equity
BioNexus Gene Lab Corp Shareholders' Equity History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$8.6M
FY2025
5-year range
$6.7M / $9.7M
FY2021-FY2025
Trend
+3.5%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Shareholders' Equity has fluctuated over the past 7 years, ranging from $1M in FY2019 to $10M in FY2023.
Based on SEC 10-K filings.
$9M in FY2025 with a 5-year CAGR of +5.3%.
Declined from $10M to $9M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +8.9%
- 5-Year CAGR
- +5.3%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +5.3%, indicating consistent growth.
- In FY2025, shareholders' equity increased 3.5% year-over-year.
- Peak shareholders' equity was recorded in FY2023.
- Lowest shareholders' equity in the period was in FY2019.
Company context
Key Data Points
- Altman Z-Score 5.27 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $8.6M | +3.5% |
| FY2024 | $8.3M | -13.8% |
| FY2023 | $9.7M | +44.9% |
| FY2022 | $6.7M | -7.2% |
| FY2021 | $7.2M | +7.8% |
| FY2020 | $6.7M | +493.6% |
| FY2019 | $1.1M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026